+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Biologics Contract Development Market Size, Share & Trends Analysis Report by Source (Mammalian, Microbial), by Product Service Type, by Disease Indication (Oncology, Immunological Disorders), by Region, and Segment Forecasts, 2020 - 2027

  • ID: 5144632
  • Report
  • August 2020
  • Region: Global
  • 144 pages
  • Grand View Research

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • Abzena Ltd.
  • AGC Biologics
  • BI BioXcellence
  • BioNova Scientific
  • Genscript
  • KBI Biopharma
  • MORE
Biologics Contract Development Market Growth & Trends

The global biologics contract development market size is expected to reach USD 11.2 billion by 2027, expanding at a CAGR of 8.8% over the forecast period. The market comprises of organizations that offer services such as the development of cell lines, upstream and downstream processes, analytical methods, and formulations. These organizations specialize in developing and manufacturing stable cell lines that are extensively used in a number of important applications including drug screening, gene functional studies, and biologics production. The market is segmented on the basis of biological source, product service (Upstream and Downstream), and disease indication. Factors such as increasing adoption of advanced technologies for biologic development, favorable environment for clinical trials in developing countries, and an increase in outsourcing of R&D activities are paving way for the growth of the market.

Growing M&A and collaboration activities between biopharma companies and CDOs are yet another factor assisting in market growth, allowing more financial stability and amalgamation of advanced and specialized technologies. For instance, in February 2020, LakePharma, Inc., and NJ Biopharmaceuticals LLC, a CRO, providing integrated chemistry and biology services, announced a strategic alliance to offer streamlined Antibody-Drug Conjugate (ADC) development solutions for biotechnology and pharmaceutical sectors. Many biopharma and pharma companies are increasingly looking for outsourcing their activities as it helps accelerate workflow (speed) of the company, provides unique specialized services, decreases drug manufacturing costs, and provides expertise. These factors are expected to boost the biologics contract development and manufacturing organization market growth in the coming years.

Biologics Contract Development Market Report Highlights
  • Mammalian source emerged as the largest product segment in 2019, as the majority of research activities are being carried out using mammalian cell lines.
  • The process development segment is expected to witness the highest CAGR over the forecast period, as many companies are opting to outsource for production of recombinant proteins and Monoclonal Antibodies (MABs).
  • North America dominated the market in 2019. An increase in strategic acquisitions and partnerships and a rise in demand for specialized testing services are likely to have a positive impact on the market.
  • In Asia Pacific, the market is expected to encounter the highest CAGR over the forecast period.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Abzena Ltd.
  • AGC Biologics
  • BI BioXcellence
  • BioNova Scientific
  • Genscript
  • KBI Biopharma
  • MORE
Chapter 1 Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Source Type
1.1.2. Product Service Type
1.1.3. Disease Indication Type
1.1.4. Regional Scope
1.1.5. Estimates and Forecast Timeline
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased Database
1.3.2. Internal database
1.3.3. Secondary Sources
1.3.4. Primary Research
1.3.5. Details Of Primary Research
1.4. Information Or Data Analysis
1.4.1. Data Analysis Models
1.5. Market Formulation & Validation
1.6. Region Wise Market Calculation
1.6.1. Region Wise Market: Base Estimates
1.6.2. Global Market: Cagr Calculation
1.7. Model Details
1.7.1. Commodity Flow Analysis (Model 1)
1.7.2. Volume Price Analysis (Model 2)
1.7.2.1. Service Segment Analysis
1.8. List Of Primary Sources
1.9. List Of Abbreviations
1.10. List Of Secondary Sources
1.11. Objectives
1.11.1. Objective-1:
1.11.2. Objective-2:
1.11.3. Objective-3:
1.11.4. Objective-4:

Chapter 2 Executive Summary
2.1 Market Outlook

Chapter 3 Biologics Contract Development Market: Variables, Trends, & Scope
3.1 Market Segmentation and Scope
3.2 Market Dynamics
3.2.1 Market Driver Analysis
3.2.2 Increasing adoption of advanced technologies
3.2.3 Increasing mergers and collaborations
3.2.4 Favourable environment for clinical trials in developing countries
3.2.5 Increasing outsourcing of R&D activities
3.2.6 Market Restraint Analysis
3.2.7 Intellectual property rights issues
3.3 Penetration & Growth Prospect Mapping
3.4 Biologics Contract Development: Market Analysis Tools
3.4.1 Industry Analysis-Porter’s
3.4.2 PESTEL Analysis

Chapter 4 Biologics Contract Development Market: Source Type Segment Analysis
4.1 Biologics Contract Development Market: Market Share Analysis, 2019 & 2027
4.1.1 Microbial
4.1.1.1 Microbial market, 2016-2027 (USD Million)
4.1.2 Mammalian
4.1.2.1 Mammalian market, 2016-2027 (USD Million)
4.1.3 Others
4.1.3.1 Others market, 2016-2027 (USD Million)

Chapter 5 Biologics Contract Development Market: Product Service Segment Analysis
5.1 Biologics Contract Development Market: Market Share Analysis, 2019 & 2027
5.2 Cell Line Development
5.2.1 Cell Line Development Market, 2016-2027 (USD Million)
5.2.1.1 Microbial Cell Line Development
5.2.1.1.1 Microbial Cell Line Development Market, 2016-2027 (USD Million)
5.2.1.2 Mammalian Cell Line Development
5.2.1.2.1 Mammalian Cell Line Development Market, 2016-2027 (USD Million)
5.2.1.3 Others
5.2.1.3.1 Others Market, 2016-2027 (USD Million)
5.3 Process Development
5.3.1 Process Development Market, 2016-2027 (USD Million)
5.3.2 Upstream Process Development
5.3.2.1 Upstream Process Development Market, 2016-2027 (USD Million)
5.3.2.1.1 Microbial
5.3.2.1.2 Microbial Market, 2016-2027 (USD Million)
5.3.2.1.3 Mammalian
5.3.2.1.4 Mammalian Market, 2016-2027 (USD Million)
5.3.2.1.5 Others
5.3.2.1.6 Others Market, 2016-2027 (USD Million)
5.3.3 Downstream Process Development
5.3.3.1 Downstream Process Development, 2016-2027 (USD Million)
5.3.3.1.1 Impurity, Isolation, & Identification
5.3.3.1.3 Physicochemical Characterization
5.3.3.1.4 Physicochemical Characterization Market, 2016-2027 (USD Million)
5.3.3.1.5 Pharmaceutical Analysis
5.3.3.1.6 Pharmaceutical Analysis Market, 2016-2027 (USD Million)
5.3.3.1.7 Others
5.3.3.1.8 Others Market, 2016-2027 (USD Million)
5.4 Downstream Process, By Product
5.4.1 Mabs (Monoclonal Antibodies)
5.4.1.1 Mabs (Monoclonal Antibodies) Market, 2016-2027 (USD Million)
5.4.2 Recombinant Proteins
5.4.2.1 Recombinant Proteins Analysis Market, 2016-2027 (USD Million)
5.4.2.1.1 Others
5.4.2.1.2 Others Market, 2016-2027 (USD Million)
5.5 Other Product Service (Quality and Regulatory Services, Etc)
5.5.1 Others Market, 2016-2027 (USD Million)

Chapter 6 Biologics Contract Development Market: Disease Indication Segment Analysis
6.1 Biologics Contract Development Market: Market Share Analysis, 2019 & 2027
6.2 Oncology
6.2.1 Oncology Market, 2016-2027 (USD Million)
6.3 Immunological Disorders
6.3.1 Immunological Disorders Market, 2016-2027 (USD Million)
6.4 Cardiovascular Disorders
6.4.1 Cardiovascular Disorders Market, 2016-2027 (USD Million)
6.5 Haematological Disorders
6.5.1 Haematological Disorders Market, 2016-2027 (USD Million)
6.5.2 Others
6.5.2.1 Others Market, 2016-2027 (USD Million)

Chapter 7 Biologics Contract Development Market: Regional Analysis
7.1 Biologics Contract Development: Regional Market Share Analysis, 2019 & 2027
7.2 North America
7.2.1 North America Biologics Contract Development Market, 2016-2027 (USD Million)
7.2.2 The U.S.
7.2.2.1 The U.S. Biologics Contract Development Market, 2016-2027 (USD Million)
7.2.3 Canada
7.2.3.1 Canada Biologics Contract Development Market, 2016-2027 (USD Million)
7.3 Europe
7.3.1 Europe Biologics Contract Development Market, 2016-2027 (USD Million)
7.3.2 The U.K.
7.3.2.1 The U.K. Biologics Contract Development Market, 2016-2027 (USD Million)
7.3.3 Germany
7.3.3.1 Germany Biologics Contract Development Market, 2016-2027 (USD Million)
7.3.4 France
7.3.4.1 France Biologics Contract Development Market, 2016-2027 (USD Million)
7.3.5 Italy
7.3.5.1 Italy Biologics Contract Development Market, 2016-2027 (USD Million)
7.3.6 Spain
7.3.6.1 Spain Biologics Contract Development Market, 2016-2027 (USD Million)
7.4 Asia Pacific
7.4.1 Asia Pacific Biologics Contract Development Market, 2016-2027 (USD Million)
7.4.2 China
7.4.2.1 China Biologics Contract Development Market, 2016-2027 (USD Million)
7.4.3 India
7.4.3.1 India Biologics Contract Development Market, 2016-2027 (USD Million)
7.4.4 Japan
7.4.4.1 Japan Biologics Contract Development Market, 2016-2027 (USD Million)
7.4.5 Australia
7.4.5.1 Australia Biologics Contract Development Market, 2016-2027 (USD Million)
7.4.6 South Korea
7.4.6.1 South Korea Biologics Contract Development Market, 2016-2027 (USD Million)
7.5 Latin America
7.5.1 Latin America Biologics Contract Development Market, 2016-2027 (USD Million)
7.5.2 Brazil
7.5.2.1 Brazil Biologics Contract Development Market, 2016-2027 (USD Million)
7.5.3 Mexico
7.5.3.1 Mexico Biologics Contract Development Market, 2016-2027 (USD Million)
7.5.4 Argentina
7.5.4.1 Argentina Biologics Contract Development Market, 2016-2027 (USD Million)
7.5.5 Colombia
7.5.5.1 Colombia Biologics Contract Development Market, 2016-2027 (USD Million)
7.6 MEA
7.6.1 MEA Biologics Contract Development Market, 2016-2027 (USD Million)
7.6.2 South Africa
7.6.2.1 South Africa Biologics Contract Development Market, 2016-2027 (USD Million)
7.6.3 Saudi Arabia
7.6.3.1 Saudi Arabia Biologics Contract Development Market, 2016-2027 (USD Million)
7.6.4 UAE
7.6.4.1 UAE Biologics Contract Development Market, 2016-2027 (USD Million)

Chapter 8 Company Profiles
8.1 Company Profiles
8.2 Company Profile
8.2.1 Wuxi Biologics
8.2.1.1 Company Overview
8.2.1.2 Financial performance
8.2.1.3 Service Benchmarking
8.2.1.4 Strategic Initiatives
8.2.2 Abzena Ltd.
8.2.2.1 Company Overview
8.2.2.2 Service benchmarking
8.2.2.3 Strategic Initiatives:
8.2.3 FUJIFILM Diosynth Biotechnologies
8.2.3.1 Company Overview
8.2.3.2 Financial performance
8.2.3.3 Service benchmarking
8.2.3.4 Strategic initiatives
8.2.4 KBI Biopharma
8.2.4.1 COMPANY overview
8.2.4.2 Service Benchmarking
8.2.4.3 Strategic Initiatives
8.2.5 AGC Biologics
8.2.5.1 Company Overview
8.2.5.2 Financial performance
8.2.5.3 Service Benchmarking
8.2.5.4 Strategic Initiatives:
8.2.6 SE Thermo Fischer (Patheon)
8.2.6.1 Company Overview
8.2.6.2 Financial performance
8.2.6.3 Service Benchmarking
8.2.6.4 Strategic Initiatives:
8.2.7 Lakepharma, Inc.
8.2.7.1 Company overview
8.2.7.2 Service Benchmarking
8.2.7.3 Strategic Initiatives:
8.2.8 Genscript
8.2.8.1 Company overview
8.2.8.2 Financial Performance
8.2.8.3 Service Benchmarking
8.2.8.4 Strategic Initiatives
8.2.9 BioNova Scientific
8.2.9.1 Company overview
8.2.9.2 Service Benchmarking
8.2.10 BI BioXcellence
8.2.10.1 Company Overview
8.2.10.2 Financial Performance
8.2.10.3 SERVICE BENCHMARKING
8.2.10.4 Strategic initiatives:
8.2.11 STC Biologics
8.2.11.1 Company Overview
8.2.11.2 Service Benchmarking
Note: Product cover images may vary from those shown
  • Wuxi Biologics
  • Abzena Ltd.
  • FUJIFILM Diosynth Biotechnologies
  • KBI Biopharma
  • AGC Biologics
  • SE Thermo Fischer (Patheon)
  • Lakepharma, Inc.
  • Genscript
  • BioNova Scientific
  • BI BioXcellence
  • STC Biologics
Note: Product cover images may vary from those shown

Loading
LOADING...

Adroll
adroll